Nurix therapeutics reports third quarter fiscal 2023 financial results and provides a corporate update

Announced strategic collaboration with seagen to develop a portfolio of degrader-antibody conjugates, resulting in a $60 million upfront payment

NRIX Ratings Summary

NRIX Quant Ranking